Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Vizamyl (flutemetamol F 18) is indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adults with cognitive impairment being evaluated for Alzheimer’s disease or other causes of cognitive decline. A negative scan suggests sparse to no neuritic plaques, reducing the likelihood of Alzheimer’s disease as the cause of cognitive impairment. A positive scan indicates moderate to frequent neuritic plaques, which are associated with Alzheimer’s disease but may also be present in other neurological conditions or in older individuals with normal cognition.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• FMM (Flutemetamol F 18) showed inconsistent diagnostic effectiveness compared to other tracers such as [¹¹C]PIB and Na[¹⁸F]F, which were more consistently effective in distinguishing ATTR amyloidosis and ATTR-CM from controls and from cardiac light chain amyloidosis.
• When evaluated alone, [¹⁸F]FMM's effectiveness in diagnosing ATTR amyloidosis was not consistently supported, with varying results reported across different studies.
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.